Cyclosporin suspension - Wellspring Ophthalmics
Alternative Names: Ciclosporin suspension - Wellspring Ophthalmics; Cyclosporin - Wellspring Ophthalmics; Cyclosporine suspension - Wellspring OphthalmicsLatest Information Update: 30 Aug 2022
At a glance
- Originator Newport Research
- Developer Wellspring Ophthalmics
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dry eyes
Most Recent Events
- 20 Jul 2022 Wellspring Ophthalmics has two patents granted, patents pending and a patent abandoned for cyclosporine dry eye therapy
- 20 Jul 2022 Preclinical in Dry eyes in USA (unspecified route)
- 23 Mar 2022 Wellspring Ophthalmics acquired patent portfolio of a novel cyclosporin dry eye therapy and intellectual property portfolio of cyclosporin formulations from Newport Research